Venture Investors Health Fund, one of the Midwest’s longest-standing healthcare-focused venture capital firms, has closed its seventh fund with $80 million in committed capital. The new fund will be used to invest in early-stage healthcare companies developing technologies that have the potential to change how patients receive care fundamentally.
Based in Madison, Wisconsin, the firm has built its reputation over four decades by supporting startups that aim to deliver more precise, personalized, and accessible healthcare while reducing costs. Unlike generalist venture capital firms, Venture Investors Health Fund focuses exclusively on innovations that can redefine care pathways rather than improve existing ones. Its portfolio includes companies such as EarliTec, which has created an eye-tracking method to diagnose autism more quickly than current standards, and HistoSonics, which uses sound energy to destroy tumors noninvasively.
The firm has a strong track record of working with university spinouts, having invested in over 40 companies emerging from research institutions such as the University of Wisconsin–Madison and the University of Michigan. This close connection to leading academic centers, along with proximity to major healthcare corporations such as Epic, GE, and Exact Sciences, provides a rich environment for collaboration and innovation.
With Fund VII, Venture Investors Health Fund plans to deepen its presence in key Midwest markets, including Minneapolis, Madison, Milwaukee, and Ann Arbor. The firm’s expertise spans medical devices, diagnostics, digital health, and pharmaceuticals, and it offers portfolio companies access to a broad advisory network and rigorous due diligence processes.
Over its history, the firm has invested in more than 80 companies, with 11 achieving exits valued between $250 million and $2.25 billion. By combining operational experience with strong syndicate partnerships, Venture Investors Health Fund aims to help founders bring groundbreaking healthcare technologies from the lab to the market, ultimately transforming the standard of care for patients.
KEY QUOTES:
“Our seventh fund reinforces our commitment to backing visionary entrepreneurs whose innovations have the potential to shift paradigms in healthcare. By focusing on technology that truly transforms how patients receive care, we aim to accelerate the translation of decades of research into real-world impact for patients and their physicians.”
Jim Adox, Managing Partner at VI
“We’re thrilled to see VI continuing to champion university research that can significantly improve human health. By partnering early on with academic innovators, Jim Adox and VI have consistently helped accelerate lab discoveries into tangible patient outcomes, which in turn strengthens our regional biotech ecosystem.”
Kelly Sexton, Associate Vice President for Research – Innovation Partnerships and Economic Impact at The University of Michigan
